A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study is to see if the standard of care subcutaneous injection of bortezomib can safely
be administered at home by the patient or caregiver. All tests and assessments are based on
standard of care procedures.